
Investments
57Portfolio Exits
3Funds
3Partners & Customers
8About Research Corporation Technologies
Research Corporation Technologies in Tucson, Ariz., is a technology investment and management company that provides early-stage funding and development for promising biomedical companies and technologies. RCT focuses on technology investments with origins from universities and research institutions worldwide. Founded in 1987, the company carries on a vision chartered in 1912 by Frederick Gardner Cottrell, a university professor and inventor who championed the transfer of academic innovation to commercial use. RCT has assets of more than $200 million to advance technology development through venture investment, partnerships and special licensing programs. To support these programs, RCT has staff in its corporate office in Tucson, Ariz., and on the Atlantic and Pacific Coasts. RCT also has an affiliate company in the United Kingdom, Cambridge Research Biolventures (CRB), and an alliance with Start-Up Australia in Sydney. Research Corporation Technologies RCT BioVentures program provides venture capital to companies whose technologies have the potential to become significant biomedical products. Their current investment interests include novel therapeutics, devices and medical technology platforms.

Want to inform investors similar to Research Corporation Technologies about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Expert Collections containing Research Corporation Technologies
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Research Corporation Technologies in 1 Expert Collection, including Advanced Materials.
Advanced Materials
1,313 items
Companies in the advanced materials space, including polymers, biomaterials, semiconductor materials, and more
Latest Research Corporation Technologies News
Jul 27, 2023
Research Corporation Technologies (RCT) led the financing round, which saw participation from ISA Ventures, Next Level Ventures and Mutual Capital Partners. RCT president Christopher Martin and Mutual Capital Partners co-founder and managing director Wayne Wallace are set to join iotaMotion’s board of directors. iotaMotion CEO Mike Lobinsky said: “The completion of this funding represents the next stage of iotaMotion’s growth as we look to capitalise on a first-to-market opportunity in the United States and expand to markets around the world.” Serving as a robotic assistant, the iotaSOFT system helps surgeons to hold the implant steadily in place while allowing them to adjust the trajectory or perform other tasks with their hands. iotaSOFT provides a cost-effective solution for hospitals to embrace CI robotics, unlike oversized robotic systems. The company’s Scientific Advisory Board has undergone expansion with the addition of Bruce Gantz, Professor Thomas Lenarz and Camille Dunn. iotaMotion board chairman Eric Timko said: “The additional funding, complemented by the expansion of our board and scientific advisors, sets up iotaMotion for tremendous success as we look to disrupt the cochlear implant market with our highly innovative technology.” Share this article
Research Corporation Technologies Investments
57 Investments
Research Corporation Technologies has made 57 investments. Their latest investment was in iotaMotion as part of their Series A - III on April 4, 2023.

Research Corporation Technologies Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
4/13/2023 | Series A - III | iotaMotion | $12M | Yes | 2 | |
3/2/2023 | Unattributed VC | Oligo Factory | Yes | 1 | ||
9/28/2022 | Series A | Pheon Therapeutics | $68M | Yes | 4 | |
7/11/2022 | Series C | |||||
5/12/2022 | Series A |
Date | 4/13/2023 | 3/2/2023 | 9/28/2022 | 7/11/2022 | 5/12/2022 |
---|---|---|---|---|---|
Round | Series A - III | Unattributed VC | Series A | Series C | Series A |
Company | iotaMotion | Oligo Factory | Pheon Therapeutics | ||
Amount | $12M | $68M | |||
New? | Yes | Yes | Yes | ||
Co-Investors | |||||
Sources | 2 | 1 | 4 |
Research Corporation Technologies Portfolio Exits
3 Portfolio Exits
Research Corporation Technologies has 3 portfolio exits. Their latest portfolio exit was Catalyst Biosciences on March 05, 2015.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
3/5/2015 | Merger | 1 | |||
Date | 3/5/2015 | ||
---|---|---|---|
Exit | Merger | ||
Companies | |||
Valuation | |||
Acquirer | |||
Sources | 1 |
Research Corporation Technologies Acquisitions
1 Acquisition
Research Corporation Technologies acquired 1 company. Their latest acquisition was Translational Drug Development on June 04, 2020.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
6/4/2020 | Acq - Fin | 3 |
Date | 6/4/2020 |
---|---|
Investment Stage | |
Companies | |
Valuation | |
Total Funding | |
Note | Acq - Fin |
Sources | 3 |
Research Corporation Technologies Fund History
3 Fund Histories
Research Corporation Technologies has 3 funds, including BioVentures Australia.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
BioVentures Australia | UNKNOWN | Unknown | 1 | ||
Cambridge Research BioVentures | |||||
RCT BioVentures |
Closing Date | |||
---|---|---|---|
Fund | BioVentures Australia | Cambridge Research BioVentures | RCT BioVentures |
Fund Type | UNKNOWN | ||
Status | Unknown | ||
Amount | |||
Sources | 1 |
Research Corporation Technologies Partners & Customers
8 Partners and customers
Research Corporation Technologies has 8 strategic partners and customers. Research Corporation Technologies recently partnered with VTU Technology on December 12, 2014.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
12/3/2014 | Partner | Austria | VTU Technology and RCT Announce Partnership `` We are delighted to offer Pichia GlycoSwitch engineered with our broad portfolio of Pichia tools in this partnership with VTU Technology and Research Corporation Technologies and I am convinced that our yield enhancing technologies will give GlycoSwitch an exciting extra edge for the production of glycoproteins with Man5 - or other human-like glycoforms '' , states Thomas Purkarthofer , Ph.D. , Head of Business Development of VTU Technology and Research Corporation Technologies . | 1 | |
12/3/2014 | Partner | ||||
6/4/2013 | Partner | ||||
7/11/2012 | Partner | ||||
6/25/2009 | Licensor |
Date | 12/3/2014 | 12/3/2014 | 6/4/2013 | 7/11/2012 | 6/25/2009 |
---|---|---|---|---|---|
Type | Partner | Partner | Partner | Partner | Licensor |
Business Partner | |||||
Country | Austria | ||||
News Snippet | VTU Technology and RCT Announce Partnership `` We are delighted to offer Pichia GlycoSwitch engineered with our broad portfolio of Pichia tools in this partnership with VTU Technology and Research Corporation Technologies and I am convinced that our yield enhancing technologies will give GlycoSwitch an exciting extra edge for the production of glycoproteins with Man5 - or other human-like glycoforms '' , states Thomas Purkarthofer , Ph.D. , Head of Business Development of VTU Technology and Research Corporation Technologies . | ||||
Sources | 1 |
Research Corporation Technologies Team
10 Team Members
Research Corporation Technologies has 10 team members, including current President, Shaun A. Kirkpatrick.
Name | Work History | Title | Status |
---|---|---|---|
Shaun A. Kirkpatrick | President | Current | |
Name | Shaun A. Kirkpatrick | ||||
---|---|---|---|---|---|
Work History | |||||
Title | President | ||||
Status | Current |
Compare Research Corporation Technologies to Competitors
Mercator MedSystems has developed a broad-based therapeutic platform that allows clinicians to accurately and efficiently deliver drugs and biologics such as stem cells to tissues deep in the body, treating the root cause of significant medical conditions. The company utilizes its family of Micro-Infusion Catheters for targeted treatments via the vascular system, including peripheral artery disease (PAD) and resistant hypertension (HTN); and via the bronchial tree, including malignant airway obstruction secondary to lung cancer. The company's 510(k)-cleared and CE-Marked Cricket and Bullfrog Micro-Infusion Catheters are vascular-access systems that are able to inject drugs, genes, and cells safely through vessel walls into deep tissues without major surgery.

Quartzy offers a cloud-based platform for laboratory management. It offers lab management solutions for small and medium-sized research and development organizations to manage their inventory, streamline purchasing communications, and consolidate orders. It was founded in 2009 and is based in Hayward, California.
J. Lamarck is a company that offers advisory services to private individuals, companies and pension funds who want to invest in the biotechnology sector.nThe company offers a high quality service and its analyst provide professional assistance to people who want to diversify a part of their portfolio in this emerging industry. Because of the nature of biotechnology investments, the company believe it is important that users work with specialists to define their portfolio strategy. Generally, specialists do things better.nOver the next few years the company will be witness of astonishing progress in health care and medicine, the company will be able to fight and cure diseases like AIDS and cancer finally. The company will also find solutions to clean up the environment and new crops that don't need pesticide. These new products will obviously boost the visibility of the companies that were at the beginning of this process on the stock market and consequently create great opportunity for it's shareholders.nJ. Lamarck wants to be their partner in this great venture.

Punjab Biotechnology Incubator (PBTI) welcomes users to its state-of-the- art Agri & Food Testing Laboratory set up at SAS Nagar (Mohali), the hub of Biotechnology and Information Technology in Punjab. PBTI is a State Govt. Undertaking registered as a "˜Society for Biotechnology Incubator' under the Society Registration Act 1961 and is professionally governed by Governing Council of the Society under the chairmanship of Chief Secretary, Govt. of Punjab. The day to day affairs are managed by Chief Executive Officer, supported by technical professionals of high caliber.

Velos provides software solutions for clinical research management. It offers a software platform with an automated research review and biospecimen management solution for trial administration, financial management, patient tracking, reporting, and many other purposes. The company was founded in 1996 and is based in Fremont, California.
Laureate Pharma, Inc. is a full service contract manufacturing organization(CMO) providing development and cGMP manufacturing services in the company's FDA registered facilities in Princeton, New Jersey. The company is dedicated to supporting the development and commercialization of biopharmaceutical, drug and diagnostic products for pharmaceutical, diagnostic and biotech companies.The company aims to provide a range of product development and manufacturing services from cell line optimization and process design to development of full-scale cGMP protein production, purification and aseptic filling, in addition to corresponding testing, validation, analytical and regulatory support. The company's focus is on mammalian cell based monoclonal antibody and recombinant protein production for clinical and modest commercial supply.The company view the company's customers as partners and provide them with flexible solutions that reduce time to clinic and market. Focused on operational excellence, the company's highly experienced staff works with the company's customers to improve the quality of their products and processes.The company value the company's customers, stakeholders and associates. Therefore, the company measure the company's success by meeting the company's customers' needs, generating results in terms of quality, timeliness and on budget performance, as well as fostering an environment of trust, growth and diversity for the company's team.